Table 1.
Clinical characteristics of the patient cohort
| Number | % | |
|---|---|---|
| Age | ||
| Median | 54 | |
| Range | 30–75 | |
| Tumor size | ||
| Median | 30 | |
| Range | 13–120 | |
| T status | ||
| T1 | 8 | 9.6 |
| T2 | 62 | 74.7 |
| T3 | 7 | 8.4 |
| T4 | 6 | 7.2 |
| N status | ||
| N0 | 40 | 48.2 |
| N1 | 32 | 38.6 |
| N2 | 7 | 8.4 |
| N3 | 4 | 4.8 |
| Stage before NAC | ||
| Stage II | 68 | 81.9 |
| Stage III | 15 | 18.1 |
| Type of surgery | ||
| Breast-conserving surgery | 38 | 45.8 |
| Mastectomy | 36 | 43.4 |
| Skin-sparing mastectomy | 8 | 9.6 |
| No operation | 1 | 1.2 |
| Type of axial surgery | ||
| Sentinel lymph node biopsy | 15 | 18.1 |
| Axial dissection after sentinel lymph node biopsy | 4 | 4.8 |
| Axial dissection | 63 | 75.9 |
| No operation | 1 | 1.2 |
| Subtype | ||
| Luminal A and luminal B | 54 | 65.1 |
| Luminal HER2 | 6 | 7.2 |
| HER2 positive | 10 | 12.0 |
| Triple negative | 13 | 15.7 |
| Nuclear grade | ||
| I | 37 | 44.6 |
| II | 20 | 24.1 |
| III | 20 | 24.1 |
| Unknown | 6 | 7.2 |
| FDG uptake | ||
| Negative | 0 | 0.0 |
| Positive | 83 | 100.0 |
| Regimens of NAC | ||
| wPAC → FEC | 39 | 47.0 |
| DOC → FEC | 39 | 47.0 |
| FEC → DOC | 2 | 2.4 |
| FEC → DOC + H | 1 | 1.2 |
| FEC → PTX + Bev | 1 | 1.2 |
| wPAC | 1 | 1.2 |
PAC paclitaxel, FEC 5-FU, epirubicin and cycrophsphamide, DOC docetaxel, H trastuzumab, Bev bevacizumab